Artisan Partners Limited Partnership Has $1.30 Billion Stock Position in argenex SE $ARGX

Artisan Partners Limited Partnership decreased its position in argenex SE (NASDAQ:ARGX) by 15.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,349,776 shares of the company’s stock after selling 436,114 shares during the quarter. argenex accounts for approximately 1.9% of Artisan Partners Limited Partnership’s holdings, making the stock its 9th largest holding. Artisan Partners Limited Partnership owned 3.84% of argenex worth $1,295,244,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Millennium Management LLC raised its position in argenex by 316.9% in the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after buying an additional 204,180 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of argenex by 1,203.4% during the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock worth $78,931,000 after acquiring an additional 123,127 shares in the last quarter. Braidwell LP raised its holdings in shares of argenex by 99.2% in the first quarter. Braidwell LP now owns 160,849 shares of the company’s stock valued at $95,201,000 after purchasing an additional 80,083 shares during the last quarter. Lord Abbett & CO. LLC lifted its position in shares of argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after purchasing an additional 68,498 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in argenex by 244.6% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 87,414 shares of the company’s stock worth $48,184,000 after purchasing an additional 62,044 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Trading Down 1.2%

ARGX stock opened at $918.53 on Wednesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.13. The business’s 50 day simple moving average is $805.61 and its 200 day simple moving average is $676.75. The firm has a market capitalization of $56.55 billion, a PE ratio of 39.44, a PEG ratio of 0.95 and a beta of 0.45.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, sell-side analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ARGX. Morgan Stanley lifted their price target on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research note on Wednesday, October 1st. Jefferies Financial Group set a $818.00 target price on argenex and gave the stock a “buy” rating in a report on Tuesday, August 26th. Stifel Nicolaus set a $882.00 price target on argenex in a research note on Thursday, September 18th. HC Wainwright boosted their price target on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $903.78.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.